Market Overview:

The global blood plasma derivatives market was valued at USD 48.27 billion in 2024 and is projected to reach USD 75.9 billion by 2033, exhibiting a CAGR of 5.2% during 2025-2033. This growth is driven by the increasing prevalence of chronic diseases, advancements in plasma collection technologies, and expanding therapeutic applications of plasma derivatives.

Study Assumption Years:

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Years: 2025-2033

Blood Plasma Derivatives Market Key Takeaways:

• Market Size and Growth: The market was valued at USD 48.27 billion in 2024 and is expected to reach USD 75.9 billion by 2033, growing at a CAGR of 5.2% from 2025 to 2033.
• Regional Dominance: North America held over 48.9% market share in 2024, driven by advanced healthcare infrastructure and a high prevalence of chronic diseases.
• Product Segmentation: Key products include albumin, factor VIII, factor IX, immunoglobulin, and hyperimmune globulin, catering to various therapeutic needs.
• Application Spectrum: Plasma derivatives are utilized in treating hemophilia, hypogammaglobulinemia, immunodeficiency diseases, and von Willebrand's disease, among others.
• End-User Insights: Hospitals and clinics are the primary end-users, reflecting the clinical importance of plasma derivatives in patient care.

Market Growth Factors:

Technological Advancements:

In recent years, plasma-derived technology has made considerable technological progress in the area of plasma fractionation and purification processes. These advances subsequently improved the efficiency and safety of plasma-derived products such as immunoglobulins and clotting factors and consequently made them more available to healthcare providers and patients. Innovations in recombinant DNA technologies also paved the way for recombinant plasma proteins, which are alternatives to traditionally plasma-derived therapies. Such technological advances are very significant in meeting the increasing global demand for plasma-derived products.

Regulatory Approvals and Supportive Policies:

Government initiatives and favorable reimbursement policies have significantly contributed to market expansion. Regulatory agencies, such as the U.S. FDA, have approved the new plasma-derived therapies, thereby facilitating their entry into the market increased acceptance. For instance, in November 2023, Takeda Pharmaceuticals received FDA approval for ADYNOVATE, a recombinant factor VIII therapy for hemophilia A patients. This kind of endorsement improves patient access to modern treatments and promotes further R&D initiatives in the industry.

Increased Prevalence of Chronic Diseases:

A major reason for the increasing demand for plasma derivatives is the rising incidence of chronic and rare diseases like hemophilia, immunodeficiency disorders, and autoimmune diseases. These diseases generally require prolonged management through plasma products; therefore, a reliable supply chain is vital. The increasing age of the world population feeds into the demand, as elders become susceptible to these disorders. Therefore, market growth continues to be due to an increasing demand for effective plasma-derived treatments.

 Request Sample For PDF Report: https://www.imarcgroup.com/blood-plasma-derivatives-market/requestsample

Market Segmentation:

Analysis by Type:

• Albumin
• Factor VIII
• Factor IX
• Immunoglobulin
• Hyperimmune Globulin
• Others

Analysis by Application:

• Hemophilia
• Hypogammaglobulinemia
• Immunodeficiency Diseases
• Von Willebrand's Disease
• Others

Analysis by End User:

• Hospitals
• Clinics
• Others

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Key Players:

• Baxter International Inc.
• Bayer AG
• CSL Limited
• Fusion Health Care Pvt. Ltd.
• Grifols S.A.
• Kedrion S.p.A.
• LFB S.A.
• Octapharma AG
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.